Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta).
Tenofovir has been shown to cross the placenta in quantities sufficient to sustain reductions in viral load in simian immunodeficiency virus (SIV)-infected fetal monkeys. With chronic exposure (30 mg/kg), however, significant bone-related toxicity has been shown in approximately 25% of infants studied. Further investigations were conducted to determine whether the bone-related toxicity observed was initiated during fetal life. Gravid rhesus monkeys (n = 4) were administered tenofovir subcutaneously once daily from 20 to 150 days of gestation (30 mg/kg; term: 165 +/- 10 days). Fetuses were monitored sonographically, and maternal and fetal blood and urine samples were collected to assess hematologic parameters, clinical chemistry, insulin-like growth factor (IGF) levels, and bone biomarkers. Fetuses were delivered by hysterotomy near term for necropsy and evaluation of bone-related mechanical properties. Results of these studies have shown 1) normal fetal development, although overall body weights and crown-rump lengths were less than those for age-matched controls (p < or = .03); 2) a significant reduction in circulating IGF-I (p <.001); 3) a small reduction in fetal bone porosity (p < or = .03); and 4) transient alterations in maternal body weights and bone-related biomarkers during the treatment period. The results of these studies suggest that chronic fetal exposure to tenofovir at the maternal dose of 30 mg/kg throughout gestation can alter select fetal parameters and transiently affect maternal bone biomarkers.
Tarantal
Alice F
AF
California Regional Primate Research Center, University of California at Davis, 95616-8542, USA. aftarantal@primate.ucdavis.edu
Castillo
Alesha
A
Ekert
Jason E
JE
Bischofberger
Norbert
N
Martin
R Bruce
RB
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000633:toxicity*; D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity*; D001835:Body Weight; D001842:Bone and Bones / Q000187:drug effects* / Q000196:embryology / Q000502:physiology; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D005333:Fetus / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D020073:Gravidity; D008253:Macaca mulatta / Q000196:embryology / Q000502:physiology*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity*; D013002:Somatomedins / Q000032:analysis; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D013002:Somatomedins; D000068698:Tenofovir; D000225:Adenine